{"entity":{"id":"nct06961565","kind":"trial","name":"PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas","aka":[],"tldr":"A phase 1 trial of PAS-004 run by Pasithea Therapeutics Corp., now recruiting.","summary":"PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas is a phase 1 interventional study registered as NCT06961565 by Pasithea Therapeutics Corp., with 56 participants planned, started 2025-05-30. Conditions recorded: NF1 Mutation, Neurofibroma Plexiform, Neurofibroma, Plexiform, Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs) and Neurofibromatosis Type 1 (NF1). Interventions recorded: PAS-004 Tablets and PAS-004 Capsule.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06961565","url":"https://clinicaltrials.gov/study/NCT06961565"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pas-004"],"companies":["pasithea-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06961565","phase":"1","setting":"A Phase 1/1b Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PAS-004, a MAPK/ERK Kinase 1/2 (MEK 1/2) Inhibitor, in Adult Participants With Neurofibromatosis Type 1 (NF1) With Symptomatic and Inoperable, Incompletely Resected, or Recurrent Plexiform Neurofibromas","sponsor":"Pasithea Therapeutics Corp.","enrolled":56,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06961565/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pas-004","kind":"drug","name":"PAS-004","route":"/drugs/pas-004/"}],"company":[{"id":"pasithea-therapeutics","kind":"company","name":"Pasithea Therapeutics","route":"/companies/pasithea-therapeutics/"}]}}